Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
Bulios Fair Price
$9.01
28.3% downside
Current Price
$12.56
According to Bulios Fair Price, CRVS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Corvus Pharmaceuticals, Inc. (CRVS) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of various types of cancer. Their primary goal is to discover and develop innovative therapies targeting the immune system that focus on specific immune pathways and interactions between tumors and the host immune system. Among their main products are drugs based on immune checkpoint inhibitors and immune response modulators, which have the potential to improve the treatment of various types of cancer and increase patient survival.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard A. Miller
Employees
37
Headquarters
South San Francisco
Upcoming events
Earnings
Upcoming earnings report